Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.57 |
| ▸ | ATP4A | P20648 | 1/20 | 0.50 |
| ▸ | ATP4B | P51164 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21017655 | 0.95 | ACHE (0.65) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL21017844 | 0.90 | CHEK2 (0.66) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL20982498 | 0.89 | CHEK2 (0.60) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL21017825 | 0.89 | ACHE (0.67) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL20982736 | 0.86 | CHEK2 (0.57) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL21017583 | 0.86 | ACHE (0.64) | ACHECHEK2ATP4AATP4B | |
| SCHEMBL21018530 | 0.85 | ACHE (0.55) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL21017228 | 0.85 | ACHE (0.66) | ACHECHEK2ATP4AATP4BALOX5 | |
| SCHEMBL20982619 | 0.85 | CHEK2 (0.72) | ACHECHEK2ATP4AATP4B | |
| SCHEMBL21018380 | 0.84 | CHEK2 (0.71) | ACHECHEK2ATP4AATP4BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3710442-A2 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | The Scripps Research Institute (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | ACHE 2382/4885CHEK2 1163/4885ATP4A 1772/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | ACHE 2382/4885CHEK2 1163/4885ATP4A 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.